Ranitidine Hydrochloride (AH19065) is a member of the class of histamine H2-receptor antagonists with antacid activity. Ranitidine is a competitive and reversible inhibitor of the action of histamine, released by enterochromaffin-like (ECL) cells, at the histamine H2-receptors on parietal cells in the stomach, thereby inhibiting the normal and meal-stimulated secretion of stomach acid. In addition, other substances that promote acid secretion have a reduced effect on parietal cells when the H2 receptors are blocked.

H2 receptor:3.3 ± 1.4 μM

Ranitidine Hydrochloride 在大鼠体内导致肝损伤，现象是Ranitidine Hydrochloride 给药后6小时内血清谷丙转氨酶、谷草转氨酶和γ-谷氨酰转移酶活性的增加。[1] Ranitidine Hydrochloride 抑制了肝缺血/再灌注在大鼠体内引发的肝组织肿瘤坏死因子α、细胞因子诱导的中性粒细胞趋化因子的增加和中性粒细胞在肝脏的积累。[2] Ranitidine Hydrochloride 联合治疗在肝损伤发生前增强了内毒素诱导的凝血，而抗凝剂抑制了内毒素/Ranitidine Hydrochloride 处理的大鼠肝损伤。Ranitidine Hydrochloride /内毒素处理的大鼠在肝窦内形成了纤维蛋白凝块且与预防纤维蛋白沉积与降低肝细胞损伤相关。Ranitidine Hydrochloride 联合治疗增强了内毒素在大鼠肝细胞损伤发生前的肿瘤坏死因子的数量。[4] 在提高十字迷宫测试中，Ranitidine Hydrochloride 显现出抗焦虑效果，这表现为大鼠在开放臂区域的停留时间增加，开放臂的探查行为增多以及末梢探险次数的增加。[5]

Ranitidine Hydrochloride 在大鼠体内导致肝损伤，现象是Ranitidine Hydrochloride 给药后6小时内血清谷丙转氨酶、谷草转氨酶和γ-谷氨酰转移酶活性的增加。[1] Ranitidine Hydrochloride 抑制了肝缺血/再灌注在大鼠体内引发的肝组织肿瘤坏死因子α、细胞因子诱导的中性粒细胞趋化因子的增加和中性粒细胞在肝脏的积累。[2] Ranitidine Hydrochloride 联合治疗在肝损伤发生前增强了内毒素诱导的凝血，而抗凝剂抑制了内毒素/Ranitidine Hydrochloride 处理的大鼠肝损伤。Ranitidine Hydrochloride /内毒素处理的大鼠在肝窦内形成了纤维蛋白凝块且与预防纤维蛋白沉积与降低肝细胞损伤相关。Ranitidine Hydrochloride 联合治疗增强了内毒素在大鼠肝细胞损伤发生前的肿瘤坏死因子的数量。[4] 在提高十字迷宫测试中，Ranitidine Hydrochloride 显现出抗焦虑效果，这表现为大鼠在开放臂区域的停留时间增加，开放臂的探查行为增多以及末梢探险次数的增加。[5]